The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023.
GBD 2023 Cancer Collaborators
https://pubmed.ncbi.nlm.nih.gov/41015051/Actively Recruiting
Led by West China Hospital · Updated on 2026-06-09
54
Participants Needed
2
Research Sites
25 weeks
Total Duration
Researchers are investigating a novel vaccine made from irradiated tumor cells and stromal cells combined with an adjuvant to address advanced solid tumors. These tumors are challenging to treat due to their complex nature and the immunosuppressive environment around them. This first-in-human Phase I study aims to evaluate the safety and tolerability of this vaccine in patients with various advanced cancers, including osteosarcoma, pancreatic cancer, head and neck, colon, liver, glioma, and triple-negative breast cancer. Participants receive the vaccine through injections, either subcutaneously or into the bone, depending on the cancer type. The vaccination schedule includes a priming phase with doses on Days 0, 14, and 28, followed by booster doses given every 28 days at the investigators discretion. Some participants also receive the drug Regorafenib alongside the vaccine for osteosarcoma. Dose escalation follows a standard 33 design to monitor safety and dose-limiting toxicities at increasing dose levels. During the study, participants are closely monitored for safety and side effects up to six months after the first dose. Researchers assess tumor response, progression-free survival, and overall survival up to 12 months. Blood samples and tumor biopsies are analyzed to observe immune changes and identify markers that could predict response to treatment. The total participation time varies, with ongoing evaluation of participants health and treatment effects throughout the study.
CONDITIONS
Clinical Study of Novel Therapeutic Vaccine for Advanced Solid Tumors
X
Xingchen Peng, Professor
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
West China Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit
Duration - 4 weeks
Participants receive the initial vaccine doses via subcutaneous or intracalvariosseous injection on Days 0, 14, and 28 to start immune activation.
3 visits for vaccine administration
Duration - Up to 6 months
Participants receive booster vaccine doses every 28 days at the investigator's discretion to maintain and enhance immune response.
Periodic visits every 28 days
Duration - Up to 12 months
Participants are monitored for safety, tumor response, and immune changes up to 12 months after the first dose.
Regular follow-up visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
9
Have more questions? Get in touch with our team for quick support
GBD 2023 Cancer Collaborators
https://pubmed.ncbi.nlm.nih.gov/41015051/Martin K Hunn, Kathryn J Farrand, Kate W R Broadley...
https://pubmed.ncbi.nlm.nih.gov/23147997/MacLean C Sellars, Catherine J Wu, Edward F Fritsch
https://pubmed.ncbi.nlm.nih.gov/35835100/Fanglong Wu, Jin Yang, Junjiang Liu...
https://pubmed.ncbi.nlm.nih.gov/34108441/Zhiruo Song, Yujie Jiang, Yu Zhang...
https://pubmed.ncbi.nlm.nih.gov/41947668/John Nemunaitis
https://pubmed.ncbi.nlm.nih.gov/12932654/Maosen Xu, Tao Zhang, Ruolan Xia...
https://pubmed.ncbi.nlm.nih.gov/36324128/Lorenzo Mortara, Valeria Frangione, Patrizia Castellani...
https://pubmed.ncbi.nlm.nih.gov/19395374/Chao Liu, Xue Liu, Xinchu Xiang...
https://pubmed.ncbi.nlm.nih.gov/35410368/Matthew J Frank, Michael S Khodadoust, Debra K Czerwinski...
https://pubmed.ncbi.nlm.nih.gov/32558897/West China Hospital
Lead Sponsor